中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 6
Jun.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(6): 1318-1324

Value of Helicobacter pylori infection combined with traditional risk factors in predicting the risk of metabolic associated fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2023.06.011
  • 1.

    Clinical Medical College, Inner Mongolia Minzu University, Tongliao, Inner Mongolia 028000, China

  • 2.

    Department of Gastroenterology, Affiliated Hospital of Inner Mongolia Minzu University, Tongliao, Inner Mongolia 028000, China

  • 3.

    Medical College, Inner Mongolia Minzu University, Inner Mongolia 028000, China

More Information
  • Corresponding author: GE Hongyan, gehongyan_1999@126.com(ORCID: 0000-0003-3691-2805)
  • Received Date: 2022-10-09
  • Accepted Date: 2023-02-13
  • Published Date: 2023-06-20
    Abstract
  •   Objective  To investigate the association between Helicobacter pylori (HP) infection and newly named "metabolic associated fatty liver disease (MAFLD)" and the value of HP infection combined with traditional risk factors in predicting MAFLD.  Methods  A retrospective analysis was performed for the clinical data of 350 patients who were admitted to Affiliated Hospital of Inner Mongolia University for the Nationalities and underwent carbon-13 urea breath test from January 2017 to December 2021, and according to whether fatty liver disease was diagnosed by abdominal ultrasound, they were divided into MAFLD group with 190 patients and non-fatty liver disease group with 160 patients. The independent-samples t test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U rank sum test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups. The binary Logistic regression analysis was used to investigate the risk factors for MAFLD.  Results  Compared with the non-fatty liver disease group, the MAFLD group had significantly higher body mass index (t=8.73, P < 0.05), systolic blood pressure (Z=-3.67, P < 0.05), diastolic blood pressure (Z=-3.62, P < 0.05), triglyceride (Z=-8.93, P < 0.05), fasting blood glucose (Z=-9.13, P < 0.05), aspartate aminotransferase (Z=-2.03, P < 0.05), gamma-glutamyl transpeptidase (Z=-8.56, P < 0.05), proportion of male patients (χ2=12.09, P < 0.05), and proportion of patients with hypertension (χ2=37.91, P < 0.05), diabetes (χ2=73.62, P < 0.05), overweight/obesity (χ2=42.82, P < 0.05), hypertriglyceridemia (χ2=59.12, P < 0.05), or HP infection (χ2=4.53, P < 0.05), as well as a significantly lower level of high-density lipoprotein cholesterol (Z=-6.81, P < 0.05). The Logistic regression analysis showed that fasting blood glucose (odds ratio [OR]=1.255, 95% confidence interval [CI]: 1.091-1.445, P < 0.05), HP infection (OR=1.899, 95%CI: 1.048-3.440, P < 0.05), hypertension (OR=2.589, 95%CI: 1.468-4.567, P < 0.05), diabetes (OR=2.202, 95%CI: 1.123-4.315, P < 0.05), overweight/obesity (OR=4.571, 95%CI: 2.308-9.052, P < 0.05), and hypertriglyceridemia (OR=4.187, 95%CI: 2.411-7.271, P < 0.05) were risk factors for MAFLD, and it also showed that HP infection combined with traditional risk factors significantly increased the risk of MAFLD in subjects with diabetes, overweight/obesity, hypertriglyceridemia, and hypertension (OR=12.267, 14.005, 7.911, and 7.364, all P < 0.05).  Conclusion  HP infection is associated with an increased risk of MAFLD, and its combination with traditional risk factors may further increase the risk of MAFLD.

     

    • FullText(HTML)
  • loading
    • References(35)
  • [1]
    MAK LY, YUEN MF, SETO WK. Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement"[J]. J Hepatol, 2020, 73(6): 1573-1574. DOI: 10.1016/j.jhep.2020.07.008.
    [2]
    ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. e1. DOI: 10.1053/j.gastro.2019.11.312.
    [3]
    ESLAM M, SARIN SK, WONG VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int, 2020, 14(6): 889-919. DOI: 10.1007/s12072-020-10094-2.
    [4]
    DOULBERIS M, PIERRE NT, MANZINI G, et al. Helicobacter pylori-related metabolic parameters and premalignant gastric mucosa histological lesions in swiss bariatric patients[J]. Microorganisms, 2021, 9(7): 1361. DOI: 10.3390/microorganisms9071361.
    [5]
    ABENAVOLI L, MILIC N, MASARONE M, et al. Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori[J]. Med Hypotheses, 2013, 81(5): 913-915. DOI: 10.1016/j.mehy.2013.08.011.
    [6]
    ZHANG S, LIU XH, WANG G, et al. Population differences of metabolic associated fatty liver disease and nonalcoholic fatty liver disease based on a community elderly population[J]. J Clin Hepatol, 2022, 38(3): 547-552. DOI: 10.3969/j.issn.1001-5256.2022.03.011.

    张爽, 刘晓慧, 王罡, 等. 基于社区老人群比较代谢相关脂肪性肝病与非酒精性脂肪性肝病的人群差异[J]. 临床肝胆病杂志, 2022, 38(3): 547-552. DOI: 10.3969/j.issn.1001-5256.2022.03.011.
    [7]
    TANG DM, CHASCSA DM, CHOU JY, et al. Helicobacter pylori infection is strongly associated with metabolic syndrome, and weakly associated with non-alcoholic fatty liver disease, in a US Hispanic population[J]. GastroHep, 2019, 1(6): 325-331. DOI: 10.1002/ygh2.375.
    [8]
    HEYDARI K, YOUSEFI M, ALIZADEH-NAVAEI R, et al. Helicobacter pylori infection and non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Turk J Gastroenterol, 2022, 33(3): 171-181. DOI: 10.5152/tjg.2022.21467.
    [9]
    LIN S, HUANG J, WANG M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world[J]. Liver Int, 2020, 40(9): 2082-2089. DOI: 10.1111/liv.14548.
    [10]
    CHOI JM, PARK HE, HAN YM, et al. Non-alcoholic/metabolic-associated fatty liver disease and helicobacter pylori additively increase the risk of arterial stiffness[J]. Front Med (Lausanne), 2022, 9: 844954. DOI: 10.3389/fmed.2022.844954.
    [11]
    WEI L, DING HG. Relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease: What should we expect from a meta-analysis?[J]. Medicine (Baltimore), 2021, 100(31): e26706. DOI: 10.1097/MD.0000000000026706.
    [12]
    JIANG T, CHEN X, XIA C, et al. Association between Helicobacter pylori infection and non-alcoholic fatty liver disease in North Chinese: a cross-sectional study[J]. Sci Rep, 2019, 9(1): 4874. DOI: 10.1038/s41598-019-41371-2.
    [13]
    ABDEL-RAZIK A, MOUSA N, SHABANA W, et al. Helicobacter pylori and non-alcoholic fatty liver disease: A new enigma?[J]. Helicobacter, 2018, 23(6): e12537. DOI: 10.1111/hel.12537.
    [14]
    FAN N, PENG L, XIA Z, et al. Helicobacter pylori Infection is not associated with non-alcoholic fatty liver disease: a cross-sectional study in China[J]. Front Microbiol, 2018, 9: 73. DOI: 10.3389/fmicb.2018.00073.
    [15]
    MOHAMMADIFARD M, SAREMI Z, RASTGOO M, et al. Relevance between Helicobacter pylori Infection and non-alcoholic fatty liver disease in Birjand, Iran[J]. J Med Life, 2019, 12(2): 168-172. DOI: 10.25122/jml-2019-0012.
    [16]
    CHENG DD, HE C, AI HH, et al. The possible role of helicobacter pylori infection in non-alcoholic fatty liver disease[J]. Front Microbiol, 2017, 8: 743. DOI: 10.3389/fmicb.2017.00743.
    [17]
    BOECKMANS J, ROMBAUT M, DEMUYSER T, et al. Infections at the nexus of metabolic-associated fatty liver disease[J]. Arch Toxicol, 2021, 95(7): 2235-2253. DOI: 10.1007/s00204-021-03069-1.
    [18]
    OKUSHIN K, TSUTSUMI T, IKEUCHI K, et al. Helicobacter pylori infection and liver diseases: Epidemiology and insights into pathogenesis[J]. World J Gastroenterol, 2018, 24(32): 3617-3625. DOI: 10.3748/wjg.v24.i32.3617.
    [19]
    LEE CH, LUI DT, LAM KS. Non-alcoholic fatty liver disease and type 2 diabetes: An update[J]. J Diabetes Investig, 2022, 13(6): 930-940. DOI: 10.1111/jdi.13756.
    [20]
    KANWAL S, GHAFFAR T, AAMIR AH, et al. Frequency of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus and its associated risk factors[J]. Pak J Med Sci, 2021, 37(5): 1335-1341. DOI: 10.12669/pjms.37.5.4211.
    [21]
    MA HL, QUAN L, JIANG S. Analysis of clinical characteristics and risk factors in patients with nonal-coholic fatty liver disease complicated with type 2 diabetes mellitus[J]. China Med Herald, 2022, 19(21): 70-73, 82. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202221016.htm

    马海林, 权莉, 蒋升. 非酒精性脂肪性肝病合并2型糖尿病患者的临床特征及危险因素分析[J]. 中国医药导报, 2022, 19(21): 70-73, 82. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202221016.htm
    [22]
    KAYA E, YILMAZ Y. Metabolic-associated Fatty Liver Disease (MAFLD): A multi-systemic disease beyond the liver[J]. J Clin Transl Hepatol, 2022, 10(2): 329-338. DOI: 10.14218/JCTH.2021.00178.
    [23]
    HAN L, ZHANG Y, YUE C, et al. Preliminary study on risk factors for morbidity of nonalcoholic fatty liver disease in high-income male population[J]. J Healthc Eng, 2022, 2022: 9331284. DOI: 10.1155/2022/9331284.
    [24]
    LI H, GUO M, AN Z, et al. Prevalence and risk factors of metabolic associated fatty liver disease in Xinxiang, China[J]. Int J Environ Res Public Health, 2020, 17(6): 1818. DOI: 10.3390/ijerph17061818.
    [25]
    CHEN YL, LI H, LI S, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study[J]. BMC Gastroenterol, 2021, 21(1): 212. DOI: 10.1186/s12876-021-01782-w.
    [26]
    LIU Y, LI D, LIU Y, et al. Association between helicobacter pylori infection and non-alcoholic fatty liver disease, hepatic adipose deposition and stiffness in southwest China[J]. Front Med (Lausanne), 2021, 8: 764472. DOI: 10.3389/fmed.2021.764472.
    [27]
    SIDDIQUI B, KAMRAN M, TIKMANI SS, et al. Frequency and risk factors of non-alcoholic fatty liver disease in Helicobacter pylori-infected dyspeptic patients: A cross-sectional study[J]. SAGE Open Med, 2021, 9: 20503121211025421. DOI: 10.1177/20503121211025421.
    [28]
    BAEG MK, YOON SK, KO SH, et al. Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2016, 22(8): 2592-2600. DOI: 10.3748/wjg.v22.i8.2592.
    [29]
    KIM TJ, LEE H, KANG M, et al. Helicobacter pylori is associated with dyslipidemia but not with other risk factors of cardiovascular disease[J]. Sci Rep, 2016, 6: 38015. DOI: 10.1038/srep38015.
    [30]
    SUMIDA Y, KANEMASA K, IMAI S, et al. Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease[J]. J Gastroenterol, 2015, 50(9): 996-1004. DOI: 10.1007/s00535-015-1039-2.
    [31]
    GOO MJ, KI MR, LEE HR, et al. Helicobacter pylori promotes hepatic fibrosis in the animal model[J]. Lab Invest, 2009, 89(11): 1291-1303. DOI: 10.1038/labinvest.2009.90.
    [32]
    YU LY, HU KC, LIU CJ, et al. Helicobacter pylori infection combined with non-alcoholic fatty liver disease increase the risk of atherosclerosis: Focus in carotid artery plaque[J]. Medicine (Baltimore), 2019, 98(9): e14672. DOI: 10.1097/MD.0000000000014672.
    [33]
    CHEN C, ZHANG C, WANG X, et al. Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism, inflammatory reaction and metabolic syndrome[J]. Eur J Gastroenterol Hepatol, 2020, 32(7): 857-866. DOI: 10.1097/MEG.0000000000001601.
    [34]
    JAMALI R, MOFID A, VAHEDI H, et al. The effect of helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized open-label clinical trial[J]. Hepat Mon, 2013, 13(12): e14679. DOI: 10.5812/hepatmon.14679.
    [35]
    YU YY, TONG YL, WU LY, et al. Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial[J]. Sci Rep, 2022, 12(1): 19530. DOI: 10.1038/s41598-022-23746-0.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (322) PDF downloads(56) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return